SMS Pharmaceuticals Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Attractively valued vs sector (P/E 35.9x vs industry 54.7x)
- Low debt relative to equity (D/E 0.5x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SMSPHARMA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 64.32% | 64.67% | 64.67% | 64.67% | 64.67% | 66.27% |
| FII | 0.59% | 0.17% | 0.18% | 0.52% | 0.31% | 0.08% |
| DII | — | 1.98% | 2.13% | 2.55% | 2.55% | 2.43% |
| Public | 35.10% | 33.18% | 33.03% | 32.27% | 32.47% | 31.23% |
Latest News
All newsSMS Pharmaceuticals receives new credit rating
*SMS Pharmaceuticals receives new credit rating.* The company has been assigned a credit rating as per a regulatory filing on the NSE. Details include short-term and long-term debt assessment by the rating agency. The rating reflects stable outlook with **'IND AA+'** for long-term and **'IND A1+'** for short-term. 📊 *STOCKS:* SMSLTD | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CreditRating
SMS Pharmaceuticals sees spurt in trading volume
*SMS Pharmaceuticals sees spurt in trading volume* — SMS Pharmaceuticals witnessed a significant increase in trading volume, prompting the NSE to seek clarification. The company has responded to the exchange’s query to ensure transparency. No major corporate announcement was disclosed. 📊 *STOCKS:* SMSLTD | 🏢 *SECTOR:* Pharma | #LOWIMPACT #VolumeSpurt
SMS Pharma releases sustainability report for FY25-26
*SMS Pharma releases sustainability report for FY25-26*. SMS Pharmaceuticals Limited has filed its Business Responsibility and Sustainability Report for FY2025-26. The report outlines the company's ESG initiatives and sustainable business practices. While informative, it contains no financial or operational updates. 📊 *STOCKS:* $SMSLTD | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Sustainability
SMS Pharma to hold shareholder meeting on Sep 29
*SMS Pharma to hold shareholder meeting on Sep 29* as per a corporate filing. The agenda and details will be announced closer to the date. Such meetings typically cover board elections, auditors, or policy approvals. No immediate financial impact expected. 📊 *STOCKS:* $SMSL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ShareholdersMeeting
SMS Pharma shifts 38th AGM date
*SMS Pharma shifts 38th AGM date.* The company has rescheduled its 38th Annual General Meeting to a new date. The revised schedule is now available in the NSE filing. No financial or operational changes were disclosed. 📊 *STOCKS:* $SMSL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
SMS Pharma informs on TDS on dividend payout
*SMS Pharma informs on TDS on dividend payout.* The company has issued an intimation regarding tax deduction at source on dividend payments as per applicable regulations. This is a routine compliance update with no immediate financial impact. Investors should note the standard TDS provisions on dividend income. 📊 *STOCKS:* $SMSLTD | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Dividend